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ABSTRACT
Introduction Glycaemic variability and other metrics are
not well characterised in subjects without diabetes. More
comprehensive sampling as obtained with continuous
glucose monitoring (CGM) may improve diagnostic
accuracy of the transition from health to pre-diabetes.
Our goal is to investigate the glycaemic system as it
shifts from health to pre-disease in adult patients without
diabetes using CGM metrics. New insights may offer
therapeutic promise for reversing dysglycaemia more
successfully with dietary, nutritional and lifestyle change
before progression occurs to pre-diabetes and diabetes.
Methods and analysis This systematic review will
include comprehensive searches of the PubMed, Scopus,
Cochrane Library and ClinicalTrials.gov databases, with
restrictions set to studies published in the last 10 years
in English and planned search date 10 March 2022.
Reference lists of studies that meet eligibility criteria in
the screening process will subsequently be screened for
the potential inclusion of additional studies. We will include
studies that examine CGM use and report diagnostic
criteria such as fasting glucose and/or haemoglobin A1c
such that we can assess correlation between CGM metrics
and established diagnostic criteria and describe how
CGM metrics are altered in the transition from health to
pre-diabetes. The screening and data extraction will be
conducted by two independent reviewers using Covidence.
All included papers will also be evaluated for quality and
publication bias using Cochrane Collaboration risk of bias
tools. If there are two or more studies with quantitative
estimates that can be combined, we will conduct a meta-
analysis after assessing heterogeneity.
Ethics and dissemination The systematic review
methodology does not require formal ethical review due
to the nature of the study design. Study findings will be
publicly available and published in a peer-reviewed journal.
PROSPERO registration number CRD42022308222.

INTRODUCTION
Rates of pre-diabetes and diabetes continue
to increase in prevalence. Pre-diabetes affects
88 million adults, more than one in three
US adults.1 However, most people with pre-
diabetes are undiagnosed or unaware. Pre-
diabetes is thought to be an intermediate state

STRENGTHS AND LIMITATIONS OF THIS STUDY
⇒ To our knowledge, this will be the first systematic

⇒

⇒

⇒
⇒

review and meta-analysis to compare continuous
glucose monitoring metrics with the gold standard
for diagnosis of health or pre-diabetes in a population without diabetes.
The evidence is determined through a systematic
search in four biomedical databases and targeted
searching of the grey literature in relevant conference proceedings.
The Covidence systematic review software will be
used for blinded screening, conflict resolving, data
extraction and quality assessment by three independent reviewers.
The Cochrane Collaboration risk of bias tools will be
used for evaluating quality and risk of bias.
Limitations include a bias for studies published in
English in the past 10 years, with adult subjects in
age range from 18 to 65 years.

of hyperglycaemia with glycaemic parameters above normal but below the diabetes
threshold. Further, the gold standard of
blood sugar measurement from the American Diabetes Association—fasting glucose,
glycosylated haemoglobin (haemoglobin A1c
or HbA1c) and oral glucose tolerance testing
in response to a 75-gram glucose load2—is
limited because they diagnose dysglycaemia
late in the pathophysiological process when it
may be more difficult to reverse. Pre-diabetes
represents worsening fasting glucose and/or
impaired glucose tolerance, but definitions
vary, leading to significant practice disparity
and low guideline adherence.3 Additionally,
there are racial and gender disparities in pre-
diabetes screening.4
Glycaemic variability and other continuous glucose monitoring (CGM) metrics are
not well characterised in subjects without
diabetes. Normal glucose (euglycaemia)
variability on a moment-
to-
moment basis

Gottfried S, et al. BMJ Open 2022;12:e061756. doi:10.1136/bmjopen-2022-061756

1

BMJ Open: first published as 10.1136/bmjopen-2022-061756 on 25 August 2022. Downloaded from http://bmjopen.bmj.com/ on September 14, 2022 at Thomas Jefferson University.
Protected by copyright.

Continuous glucose monitoring metrics
for earlier identification of pre-diabetes:
protocol for a systematic review
and meta-analysis

Open access

Comparison
Potentially relevant CGM biomarkers are identified by
comparing pre-diabetes values with values for healthy
controls (fasting glucose <100 mg/dL, and/or HbA1c
<5.7%, and/or 2-hour OGTT with glucose <140 mg/
dL).
CGM biomarkers are then compared with standard
diagnostics for pre-diabetes.
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METHODS AND ANALYSIS
The protocol for the present systematic review and meta-
analysis follows the Preferred Reporting Items for Systematic Review and Meta-
Analysis Protocols guidelines,30
and the Cochrane Handbook of Systematic Reviews of
Interventions.31
The protocol is registered with the National Institute
for Health Research International Prospective Register of
Systematic Reviews (CRD42022308222).
Eligibility criteria
A summary of the participants, interventions, comparators and outcomes considered, as well as the type
of studies included according to PICOS strategy,32 is
provided below.
Population
The target population is adults (> 18 years old) who are
diagnosed with pre-diabetes (fasting glucose 100–125
mg/dL after a minimum 8-hour fast, and/or HbA1c
5.7–6.4%, and/or 2-hour OGTT with glucose 140–199
mg/dL) as defined by the American Diabetes Association
(https://www.diabetes.org/a1c/diagnosis,
accessed 24 January 2022). We will use the criteria of
fasting glucose 100–125 mg/dL or HbA1c of 5.7–6.4%
since the 2-hour OGTT is less commonly used in clinical practice, but we will extract the data if available.
In order to create the most homogeneous pool of
studies to address our research questions in adults
without diabetes, studies that include only participants
under the age of 18 years, above the age of 65 years, or
diagnosed with type 1 and/or type 2 diabetes will be
excluded. Studies will also be excluded if focused on
subjects with acute illness or systemic chronic disease
(eg, liver, kidney, stroke, coronary artery disease).
Intervention
We will evaluate primary studies that report outcomes
of the use of CGM in patients with pre-diabetes and/or
healthy subjects.
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Objectives
This systematic review aims to answer the following
questions:
1. How do CGM metrics differ between euglycaemia and
pre-diabetes?
2. What is the relation (correlation) between CGM dynamic metrics and established diagnostic criteria?
3. What is the diagnostic power of CGM dynamic metrics?

has yet to be elucidated. Most standards of euglycaemia
rely on targets from epidemiological studies of episodic
measurement, which document clinical labs measured
annually rather than a more comprehensive characterisation of the individual’s glycaemic status. People
with similar HbA1c and mean glucose show extremely
different daily glucose excursions and variability, leading
to debate and lack of consensus about pathophysiological pathways in the gradient from health to disease.5
Indeed, standard measurements like HbA1c are limited
because several conditions affect reliability, including
patient ethnicity; conditions that impair erythrocyte
production or alter the normal process of glycation;
and even normal ageing.6 7 Moreover, fasting glucose of
100 mg/dL may not be sufficient to separate individuals
with normoglycaemia from individuals with pre-diabetes.
Subjects with fasting glucose less than 100 mg/dL show
impaired glucose tolerance when monitored continuously for at least 24 hours.8 Subjects who are morbidly
obese and euglycaemic have higher glycaemic variability
compared with subjects with normal weight and without
diabetes.9 Some investigators use a fasting plasma glucose
level ≤5.4 mmol/L (97 mg/dL) after an overnight fast
because it has greater sensitivity to exclude diabetes in
the absence of an oral glucose tolerance test (OGTT).10
Evidence supports increased insulin resistance and up to
a threefold greater risk of diabetes when fasting glucose
exceeds 90 mg/dL.11
Excess glycaemic variability, especially postprandial,
triggers increased oxidative stress that can damage
tissues, such as blood vessels.12–14 Glycaemic variability
within the gold standard of ‘normal’ may raise cardiovascular risk and precede an increase in HbA1c.15 Glycaemic
variability may modulate cardiovascular risk even when
fasting glucose and A1c are normal.16 While most of the
data on downstream damage from excess glucose excursions are derived from patients with diabetes, the scientific literature increasingly indicates that microvascular
and macrovascular complications may occur in subjects
without diabetes.16–18 Risk may be higher in women at
lower glucose levels compared with men.19 20 Evidence
shows that characterising dysglycaemia with greater
precision uncovers higher cardiometabolic risk associated with specific glucose derangements such as postprandial hyperglycaemia,21 22 acute glucose spikes23 24 and
perhaps nocturnal hypoglycaemia.25–28 From a systems
biology perspective, the convention of single or limited
series measurement of glucose testing may be inadequate to detect downstream dysfunction, setting the
stage for more dense sampling and real-world evidence
as obtained with CGM and potentially better diagnostic
accuracy.29
Our goal is to interrogate the glycaemic system as
it shifts from health to pre-disease in patients without
diabetes using CGM metrics. New insights may offer therapeutic promise for reversing dysglycaemia more successfully with dietary, nutritional and lifestyle change before
progression occurs to pre-diabetes and diabetes.

Open access

Study design
This review includes observational (eg, case report, case
sectional, case–control, cohort) and interseries, cross-
ventional (eg, quasi-
experimental studies, randomised
controlled trials, community trials, field trials) primary,
peer-review studies in which CGM is the only intervention under investigation. We will exclude reviews, editorials, commentaries, letters, opinions, meta-analysis, case
reports, conference abstracts, comments, preclinical (in
vitro; animal model) studies and clinical trials involving
additional interventions. Studies will be restricted to
the English language and published in the last 10 years,
since for technologies that evolve and improve rapidly,
like CGM, the more recent studies (using the technology
closer to the current one) are majorly relevant.

pre-diabetes; (2) terms related to CGM; (3) terms related
to diagnostic criteria for pre-
diabetes; and (4) terms
related to diagnostic accuracy and the prediction of transition. Each set of terms includes both keywords searched
in the title/abstract field and database-specific subject
headings. Terms within each set are combined with the
operator OR. The four sets of terms are then combined
with the operator AND, yielding studies that include at
least one term from each set. The initial search strategy
was developed in PubMed (see online supplemental file
1). The strategy will be translated into the other included
databases, using appropriate subject headings for each
database.
Study selection
All records identified in the database search will be
uploaded to Covidence systematic review software
(https://www.covidence.org) for automatic deduplication and blinded screening, conflict resolving, study
selection and data extraction. Two authors will independently perform the initial primary article screening
based on the information contained in their titles and
abstracts, and categorise them into three groups: relevant, irrelevant and unsure. In case of disagreement,
the article will be re-evaluated and, if the disagreement
persists, a third reviewer will make a final decision. Full-
paper screening will then be conducted by the same
independent investigators and a list of articles to be
included in the review is compiled. Reference lists of articles that meet eligibility criteria in the screening process
will subsequently be screened for potential inclusion of
additional studies.

Search strategy
A medical librarian on the review team developed a
comprehensive search strategy encompassing the aims
of the systematic review. The strategy combines four sets
of terms with Boolean operators: (1) terms related to

Data extraction
Two independent authors will extract data from the
final studies identified as eligible to be included in the
review using a predesigned pilot-tested data collection
form using the Covidence extraction module. Eventual
discrepancies will be addressed with a third reviewer and
discussed until consensus is reached.
The data to be extracted will include:
1. Publication details: authors, title, journal, year of publication, country in which the study was conducted and
funding source(s).
2. Study design: type of study, inclusion and exclusion
criteria, method of recruitment of participants, limitations and mitigation strategies.
3. Participant details: sample size, demographic information (eg, age, gender, comorbidities).
4. Intervention characteristics: CGM device brand and
model, CGM duration and aim of intervention.
5. Study outcomes: CGM metrics, correlation between
CGM metrics and established diagnostic criteria.
In cases of missing, incomplete or unclear data in the
included studies, we will attempt to contact study authors
for further information.
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Search methods for identifying studies
Sources of studies
We will conduct systematic searches of the PubMed,
Scopus, Cochrane Library and C
 linicalTrials.
gov databases. Searches will be limited to studies published in
English within 10 years of the time of conducting the
search. We will additionally search for unpublished
studies in grey literature, by reviewing abstracts from a
targeted group of conference proceedings for potential inclusion of additional studies. When available, the
proceedings of these conferences from 2012 to 2022 will
be searched: Precision Nutrition and Metabolism Conference; Harvard Precision Medicine Annual Conference;
International Precision Medicine Conference and Precision Medicine World Conference.
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Outcomes
In order to explore and define novel CGM biomarkers
to predict transition from normal to pre-diabetic phenotype, the following outcomes are considered:
► CGM metrics include but are not limited to the
following: mean, standard deviation (SD), coefficient
of variation (CV), continuous overall net glycaemic
action (CONGA), mean amplitude of glycaemic
excursions (MAGE), mean absolute glucose (MAG),
glycaemic assessment diabetes equation (GRADE),
% time in range, % time below range, % time above
range (note that the definition of time in range may
vary by author, which will be addressed in the systematic review).
► Pearson correlation coefficient and results of error
grid analysis between the CGM system metrics and
established glucose monitoring methods (fasting
glucose, HbA1c, 2-hour OGTT).
► CGM metrics diagnostic power (eg, sensitivity, specificity, area under the curve, diagnostic OR).

Open access

Data synthesis and analysis
Data will be entered into a custom database and a narrative synthesis will summarise the findings of the review
by organising data into a systematic narrative review,
tables and figures of data extraction. For continuous
outcomes, analysis will be performed using standardised
mean differences or mean differences with its respective
95% CIs. Binary outcomes will be analysed and reported
using risk ratio or OR with its respective 95% CIs. Studies
with similar characteristics and outcomes will be grouped
and, where suitable data and homogeneity exist, a meta-
analysis will be performed using random-effects models.
A combined Pearson correlation coefficient between
CGM metrics and established diagnostic criteria (ie,
fasting plasma glucose, HbA1c, 2-hour OGTT) with 95%
CI will also be calculated. If sufficient data are available,
subgroup analysis will be carried out to explore CGM
metrics estimates for pre-diabetes stratified by age, sex,
race and ethnicity, type of CGM device and body mass
index.
Patient and public involvement
As this research will be based on previously published
data, there will be no patient and public involvement
in the design, interpretation or dissemination of the
findings.

DISCUSSION
This systematic review will provide important information about the benefits of adding CGM to standard diagnostic measures in the diagnosis of euglycaemia versus
pre-diabetes. Currently, there are many challenges that
exist with the diagnosis of pre-diabetes.36 The technology,
emerging algorithms and more comprehensive data set
have shown promise distinguishing subjects with euglycaemia from subjects with pre-diabetes at an earlier stage,
and likely before standard measures such as HbA1c show
abnormalities. Previously, Hall et al discovered that in
individuals considered to be euglycaemic by single or
episodic measurement, CGM identifies an additional
15% of patients with pre-diabetes and 2% with diabetes,
suggesting that dysglycaemia is more prevalent than
previously understood and that CGM metrics may be a
more sensitive indicator of dysglycaemia, though the cost
is certainly higher.29 The findings will inform further
work that will aim to more fully characterise the stages
in the transition from health to pre-diabetes, potentially
providing a mechanism for patients to be more involved
and empowered to reverse dysglycaemia in response to
food and lifestyle factors. There are several limitations to
the current review protocol. The review will be restricted
4

to published studies in the last 10 years, which introduces publication bias. Second, only studies written in
English language will be included, introducing language
bias. Third, we acknowledge that CGM values in subjects
without diabetes are not linked with hard outcomes like
retinopathy or nephropathy, so that the clinical relevance of our findings will remain associative only. Finally,
we note that CGM has not been validated by any health
agency for any form of diabetes or non-diabetes and that
the identified CGM metrics are exploratory.
ETHICS AND DISSEMINATION
Owing to the study design of systematic reviews and meta-
analyses, ethics approval is not necessary. The systematic
review will be published in a peer-reviewed journal and
presented at appropriate conferences. This protocol will
be adapted for the analysis of other classes of biomarkers
for pre-diabetes.
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